Legal & General Group Plc acquired a new stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 183,099 shares of the company's stock, valued at approximately $4,638,000. Legal & General Group Plc owned about 0.23% of Pediatrix Medical Group as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Global Retirement Partners LLC boosted its position in Pediatrix Medical Group by 68,250.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,367 shares of the company's stock valued at $29,000 after acquiring an additional 1,365 shares during the last quarter. Transamerica Financial Advisors LLC acquired a new stake in Pediatrix Medical Group during the fourth quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Pediatrix Medical Group during the fourth quarter worth approximately $33,000. TD Private Client Wealth LLC bought a new stake in Pediatrix Medical Group in the fourth quarter worth approximately $39,000. Finally, Los Angeles Capital Management LLC acquired a new position in Pediatrix Medical Group in the fourth quarter valued at approximately $43,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.
Pediatrix Medical Group Stock Performance
Shares of MD opened at $26.89 on Friday. The firm has a market capitalization of $2.18 billion, a P/E ratio of 12.87 and a beta of 0.64. Pediatrix Medical Group, Inc. has a 52 week low of $15.69 and a 52 week high of $27.94. The stock has a 50 day moving average price of $26.27 and a two-hundred day moving average price of $23.34. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The company had revenue of $487.78 million for the quarter, compared to analysts' expectations of $478.49 million. During the same quarter in the previous year, the firm earned $0.53 earnings per share. Pediatrix Medical Group's quarterly revenue was up 4.1% on a year-over-year basis. Equities analysts forecast that Pediatrix Medical Group, Inc. will post 2.17 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
MD has been the topic of a number of research analyst reports. UBS Group increased their price target on Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a "neutral" rating in a report on Thursday, August 6th. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a "hold" rating in a research report on Tuesday, July 14th. Jefferies Financial Group lowered shares of Pediatrix Medical Group from a "buy" rating to a "hold" rating and increased their target price for the stock from $27.00 to $28.00 in a research note on Wednesday, August 19th. Weiss Ratings cut shares of Pediatrix Medical Group from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 25th. Finally, Mizuho set a $24.00 price target on shares of Pediatrix Medical Group in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $25.00.
Read Our Latest Research Report on Pediatrix Medical Group
Pediatrix Medical Group Company Profile
(
Free Report)
Pediatrix Medical Group, Inc NYSE: MD is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
Featured Stories
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pediatrix Medical Group, Inc. (NYSE:MD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pediatrix Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.
While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.